Dyne Therapeutics, Inc.
DYN
$9.57
-$0.48-4.78%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -75.72% | -34.37% | -61.31% | -0.31% | -48.57% |
| Total Depreciation and Amortization | 30.05% | 12.78% | 1.62% | -7.42% | -6.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -35.73% | 72.55% | 68.46% | 20.78% | 308.40% |
| Change in Net Operating Assets | 89.03% | -119.92% | 215.09% | 1.05% | -314.44% |
| Cash from Operations | -34.83% | -140.92% | -47.48% | 1.39% | -67.43% |
| Capital Expenditure | -413.61% | -1,210.98% | -51.50% | -242.80% | 16.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.36% | -156.83% | -247.44% | -31.18% | -758.24% |
| Cash from Investing | 100.81% | -161.12% | -251.34% | -35.16% | -764.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -65.41% | 2,373.47% | 3,866.74% | 1,425.18% | 1,317.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -65.41% | 2,373.47% | 3,866.74% | 1,425.18% | 1,317.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.46% | -1,016.35% | -103.67% | 2,589.40% | 1,572.58% |